Escalon Medical Corp.

What they do

Escalon develops, manufactures, markets, and distributes ophthalmic medical devices, including A-Scans, B-Scans, UBM devices, pachymeters, intraocular gases, surgical packs, and the AXIS Image Management system. Operations are split between a New Berlin, WI facility for surgical products and a Lake Success, NY facility for ultrasound devices and software. The company operates as one reportable segment and sells both domestically and internationally.

Revenue drivers

• Trek products — Sales of Trek products increased approximately $114,000 in fiscal 2025 and remain a key growth driver; they were partially offset by declines in other segments.
• Sonomed products — Ultrasound equipment and services; sales decreased $33,000 in fiscal 2025 and $310,000 in the nine months ended March 31, 2026 due to backorders from a vendor's constraints.
• Service plans — Service revenue, including ultrasound and digital service, contributed $532,000 in fiscal 2025; in the latest nine months, ultrasound service rose $92,000 while digital service fell $51,000.
• AXIS Image Management — Software revenue declined $17,000 in fiscal 2025 and recorded a $98,000 retention and severance accrual associated with the sale of AXIS software in the latest quarter.

Recent performance

In fiscal 2025, revenue rose 0.5% to $12.0 million, with net income of $105,525 and positive operating cash flow of $380,725. For the nine months ended March 31, 2026, revenue fell 6.3% to $8,875,000, driven by declines in Sonomed and Trek products. Gross margin contracted to 40.8% from 46.3% due to product mix and the AXIS accrual. SG&A expenses rose 10.2% to $3,770,000, while R&D spending fell 18.4% to $377,000. The company had cash of $3.3 million and equity of $4.1 million as of March 31, 2026.

Strategy

Management is focused on product development, particularly enhancing ultrasound equipment and AXIS software, with R&D spending of $753,000 in fiscal 2025. They are addressing vendor fulfillment constraints to recover Sonomed sales and managing costs through mix improvements and consulting expense reductions. The company is also evaluating the impact of tariffs on international business and supply chain costs. Recent 8-K filings indicate a material agreement and an acquisition or disposition in January 2026.

Risks

• Going concern risk — Substantial doubt exists about the company's ability to continue as a going concern, with an accumulated deficit of $68.4 million at June 30, 2025.
• Vendor fulfillment constraints — Sonomed sales were hurt by a significant vendor's fulfillment constraints related to shifting demand, causing backorders and revenue loss.
• Tariff and supply chain exposure — Uncertainty in tariffs could impact international business and raise supply chain costs, affecting profitability.
• Regulatory and operational risks — The business is subject to FDA regulation and requires costly testing and certification, with any failure to maintain compliance potentially disrupting operations.

Outlook

Management sees the trend toward profitability but notes uncertainty about sustaining sales growth and improving liquidity. They are focused on resolving vendor issues and managing costs, while monitoring the impact of tariffs. The company's ability to continue as a going concern depends on raising capital or achieving sustained profitability.